Clinical Trial

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.
Protocol Amendment History 41 amendments
This ClinicalTrials.gov record has been amended 41 times since 2018-01-23; most recent amendment 2026-02-05.
Status change: Recruiting → Active, Not Recruiting 2021-08-16
Status change: Not Yet Recruiting → Recruiting 2018-02-21
Trial Details
NCT Number NCT03414970
Lead Sponsor Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI), Canadian Cancer Trials Group
Conditions Ductal Breast Carcinoma, Invasive Breast Carcinoma, Lobular Breast Carcinoma, Medullary Breast Carcinoma, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer +1 more
Enrollment 898 participants
Start Date 2018-03-12
Primary Completion 2024-02-01 (estimated)
Study Completion 2035-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-24